MX2010004831A - Moleculas de enlace de nogo-a mejoradas y uso farmaceutico de las mismas. - Google Patents

Moleculas de enlace de nogo-a mejoradas y uso farmaceutico de las mismas.

Info

Publication number
MX2010004831A
MX2010004831A MX2010004831A MX2010004831A MX2010004831A MX 2010004831 A MX2010004831 A MX 2010004831A MX 2010004831 A MX2010004831 A MX 2010004831A MX 2010004831 A MX2010004831 A MX 2010004831A MX 2010004831 A MX2010004831 A MX 2010004831A
Authority
MX
Mexico
Prior art keywords
binding molecule
nogo
improved
binding molecules
pharmaceutical use
Prior art date
Application number
MX2010004831A
Other languages
English (en)
Inventor
Carmen Barske
Anis Khusro Mir
Martin E Schwab
Alessandra Vitaliti
Stefan Frentzel
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39156235&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010004831(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2010004831A publication Critical patent/MX2010004831A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

La presente invención proporciona una molécula de enlace que es capaz de enlazarse al polipéptido del Nogo-A humano o del NiG humano con una constante de disociación < 1000 nM, un polinucleótido que coditica esta molécula de enlace; un vector de expresión que comprende dicho polinucleótido; un sistema de expresión que comprende un polinucleótido capaz de producir una molécula de enlace; una célula huésped aislada, la cual comprende un sistema de expresión como se define anteriormente; el uso de esta molécula de enlace como un producto farmacéutico, en especial en el tratamiento de una enfermedad del sistema nervioso periférico (PNS) y/o del sistema nervioso central (CNS); una composición farmacéutica, la cual comprende la molécula de enlace; y un método para el tratamiento de una enfermedad del sistema nervioso periférico (PNS) y/o del sistema nervioso central (CNS).
MX2010004831A 2007-11-02 2008-10-27 Moleculas de enlace de nogo-a mejoradas y uso farmaceutico de las mismas. MX2010004831A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US174107P 2007-11-02 2007-11-02
EP07119847 2007-11-02
PCT/EP2008/064501 WO2009056509A1 (en) 2007-11-02 2008-10-27 Improved nogo-a binding molecules and pharmaceutical use thereof

Publications (1)

Publication Number Publication Date
MX2010004831A true MX2010004831A (es) 2010-05-21

Family

ID=39156235

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010004831A MX2010004831A (es) 2007-11-02 2008-10-27 Moleculas de enlace de nogo-a mejoradas y uso farmaceutico de las mismas.

Country Status (30)

Country Link
US (2) US8163285B2 (es)
EP (1) EP2207808B1 (es)
JP (1) JP5698534B2 (es)
KR (1) KR101574814B1 (es)
CN (1) CN101910200B (es)
AR (1) AR072934A1 (es)
AU (1) AU2008317724B2 (es)
CA (1) CA2704357C (es)
CL (1) CL2008003240A1 (es)
CO (1) CO6270357A2 (es)
CY (1) CY1114345T1 (es)
DK (1) DK2207808T3 (es)
ES (1) ES2425768T3 (es)
HK (1) HK1143597A1 (es)
HR (1) HRP20130699T1 (es)
IL (2) IL205357A (es)
JO (1) JO2876B1 (es)
MA (1) MA31805B1 (es)
MX (1) MX2010004831A (es)
MY (1) MY149546A (es)
NZ (1) NZ584911A (es)
PE (1) PE20090981A1 (es)
PL (1) PL2207808T3 (es)
PT (1) PT2207808E (es)
RU (1) RU2513697C2 (es)
SI (1) SI2207808T1 (es)
TN (1) TN2010000199A1 (es)
TW (1) TWI429656B (es)
WO (1) WO2009056509A1 (es)
ZA (1) ZA201002799B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012004773A1 (en) 2010-07-09 2012-01-12 Universite De Geneve New uses of nogo-a inhibitors and related methods
BR112014032987A2 (pt) 2012-07-05 2017-06-27 Glaxo Group Ltd método de tratamento ou profilaxia de um distúrbio neurológico
RS63125B1 (sr) 2015-11-03 2022-05-31 Janssen Biotech Inc Antitela koja se specifično vezuju za pd-1 i njihova upotreba
KR20220087516A (ko) 2019-10-24 2022-06-24 노바고 테라퓨틱스 아게 신규 항-Nogo-A 항체
WO2024041450A1 (zh) * 2022-08-22 2024-02-29 舒泰神（北京）生物制药股份有限公司 特异性识别Nogo-A的抗体及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308573D0 (en) 1983-03-29 1983-05-05 British Nuclear Fuels Ltd Filament impregnating/coating
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DE3785186T2 (de) 1986-09-02 1993-07-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
DK0383417T3 (da) 1989-02-13 1996-05-13 Schering Ag Flagmusespyt-plasminogenaktivator v-PAalfa1
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
IL142989A0 (en) * 1998-11-06 2002-04-21 Nucleotide and protein sequences of nogo genes and methods based thereon
CN1234730C (zh) * 2001-12-30 2006-01-04 上海中科伍佰豪生物工程有限公司 鼠抗氯霉素单克隆抗体及其用途
US7531178B2 (en) 2002-06-07 2009-05-12 Trigen Gmbh Immunoadhesin comprising a glycoprotein VI domain
GB0228832D0 (en) * 2002-12-10 2003-01-15 Novartis Ag Organic compound
EP2221317A3 (en) 2003-06-30 2011-07-27 Domantis Limited PEGylated single domain antibodies (dAb)
GB0321997D0 (en) * 2003-09-19 2003-10-22 Novartis Ag Organic compound
GB0329684D0 (en) * 2003-12-22 2004-01-28 Glaxo Group Ltd Method
US7988964B2 (en) * 2003-12-22 2011-08-02 Glaxo Group Limited NOGO-a neutralising immunoglobulin for treatment of neurological diseases
KR100918746B1 (ko) 2004-09-06 2009-09-24 교와 핫꼬 기린 가부시키가이샤 항 ａ３３ 항체
DK1899377T3 (da) * 2005-07-05 2012-11-12 Glaxo Group Ltd Humaniserede antistoffer, der er specifikke for NOGO-A, og farmaceutiske anvendelser deraf.
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
EP2049567A2 (en) 2006-07-18 2009-04-22 Centocor, Inc. Human glp-1 mimetibodies, compositions, methods and uses
AR069130A1 (es) 2007-11-02 2009-12-30 Novartis Ag Moleculas de enlace de la opsonina principal del complemento (c3b) y metodos para modular el componente de complemento
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
KR101039751B1 (ko) 2008-10-16 2011-06-09 한국생명공학연구원 Ｔｍｐｒｓｓ４―특이적인 인간항체

Also Published As

Publication number Publication date
SI2207808T1 (sl) 2013-09-30
EP2207808A1 (en) 2010-07-21
JP2011502476A (ja) 2011-01-27
US20110027284A1 (en) 2011-02-03
JO2876B1 (en) 2015-03-15
CL2008003240A1 (es) 2009-06-05
US20120171215A1 (en) 2012-07-05
ES2425768T3 (es) 2013-10-17
CN101910200B (zh) 2013-12-18
HK1143597A1 (en) 2011-01-07
MY149546A (en) 2013-09-13
CA2704357A1 (en) 2009-05-07
MA31805B1 (fr) 2010-10-01
US8758754B2 (en) 2014-06-24
CO6270357A2 (es) 2011-04-20
JP5698534B2 (ja) 2015-04-08
EP2207808B1 (en) 2013-05-08
BRPI0818928A2 (pt) 2017-05-16
TN2010000199A1 (en) 2011-11-11
PT2207808E (pt) 2013-08-26
NZ584911A (en) 2011-08-26
RU2513697C2 (ru) 2014-04-20
AR072934A1 (es) 2010-09-29
TW200934791A (en) 2009-08-16
US8163285B2 (en) 2012-04-24
CN101910200A (zh) 2010-12-08
WO2009056509A1 (en) 2009-05-07
IL221723A0 (en) 2012-10-31
AU2008317724A1 (en) 2009-05-07
PE20090981A1 (es) 2009-08-13
RU2010122044A (ru) 2011-12-10
ZA201002799B (en) 2011-01-26
TWI429656B (zh) 2014-03-11
AU2008317724B2 (en) 2011-06-02
KR20100100848A (ko) 2010-09-15
PL2207808T3 (pl) 2013-11-29
CA2704357C (en) 2016-06-21
DK2207808T3 (da) 2013-08-05
IL205357A0 (en) 2010-12-30
IL205357A (en) 2014-08-31
HRP20130699T1 (hr) 2013-11-22
KR101574814B1 (ko) 2015-12-04
CY1114345T1 (el) 2016-08-31
IL221723A (en) 2014-08-31

Similar Documents

Publication Publication Date Title
TN2009000190A1 (en) Lingo binding molecules and pharmaceutical use thereof
PH12014501091A1 (en) Binding molecules for bcma and cd3
MY177065A (en) 4-1bb binding molecules
TNSN06085A1 (en) Nogo-a binding with enhanced affinity and pharmaceutical use thereof
EP3912997A3 (en) Binding molecules for bcma and cd3
NZ717429A (en) Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
UA100682C2 (ru) АНТИТЕЛО, КОТОРОЕ НЕЙТРАЛИЗУЕТ ЧЕЛОВЕЧЕСКИЙ ЦИТОМЕГАЛОВИРУС (hCMV), И ЕГО ПРИМЕНЕНИЕ
PH12015500806A1 (en) Binding molecules to the human ox40 receptor
GB201020995D0 (en) Biological materials and uses thereof
MX2009010610A (es) Dominio de enlace especifico de especies cruzadas.
TW201129379A (en) Anti-Orai1 antigen binding proteins and uses thereof
MY171038A (en) Bispecific antigen binding molecules
MX2009012950A (es) ANTICUERPOS HUMANIZADOS CONTRA EL GLOBULOMERO Aß (20-42) Y SUS USOS.
TN2010000199A1 (en) Improved nogo-a binding molecules and pharmaceutical use thereof
NZ593905A (en) Il-1 binding proteins
UA102867C2 (uk) Антитіла до cxcr4 та їх застосування у лікуванні раку
MX2011003502A (es) Anticuerpo de cadena sencilla biespecifica de psmaxcd3 especifico a traves de especies.
UA102891C2 (uk) Повні людські антитіла, специфічні до cadm1
JO2991B1 (ar) بروتينات رابطة لمولد ضد المستقبل ايه للانترليوكين 17
WO2013068430A3 (en) High mast2-affinity polypeptides and uses thereof
WO2009106532A3 (en) Use of prokaryotic tir-domain containing proteins as therapeutic and diagnostic agents
TH145975A (th) โมเลกุลเชื่อมประสาน nogo-a ที่ได้รับการปรับปรุงและการใช้ประโยชน์ทางเภสัชกรรม
TH71697A (th) โมเลกุลสำหรับจับ nogo-a และการใช้สารเหล่านี้ในทางยา
TN2011000150A1 (en) Anti cxcr4 antibodies and their use for the treatment of cancer
UA97414C2 (ru) Выделенное человеческое антитело, связывающееся с gm-csf

Legal Events

Date Code Title Description
FG Grant or registration